Overwhelming demand for transformative GLP-1 agonists like Ozempic and Mounjaro has led to widespread compounding and a boom in counterfeiting.

Is it safe or cost-effective to import medicine from Canada's or other countries' drug supplies?

 

Pharmacy Benefit Managers' under-reimbursements make pharmacies perfect targets for counterfeiters—and make the U.S. drug supply less safe as a result.

State Prescription Drug Affordability Boards intend to control medicine costs — but some of their strategies will have unintended consequences.

After two decades of tracking counterfeit drugs, PSM is an expert on medicine safety issues and we often offer journalists our insight and perspective. 

April 21, 2025: Kentucky doctor pleads guilty after injecting patients with semaglutide from unregistered sources

April 22, 2025
screenshot from a website selling vials of "research" semaglutide

A Kentucky doctor treated weight loss patients with research chemicals; CBP seized 90,000 alprazolam pills being smuggled into the U.S.

FDA Alert: Counterfeit Ozempic found in U.S. Supply Chain

April 15, 2025

The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the U.S. drug supply chain. The falsified products, labeled with lot number PAR0362 and serial numbers beginning with 51746517, were seized by the FDA on April 9, 2025. Their contents and safety are unverified and pose serious health risks.

New initiative: Best practices for online pharmacy-to-pharmacy marketplaces

April 15, 2025

PSM is seeking input on developing a set of best practices to reduce sales of counterfeit and diverted medicines on online pharmacy-to-pharmacy marketplaces.

April 14, 2025: Regulators announce a third instance of counterfeit Ozempic injections in the U.S. drug supply

April 14, 2025
Boxes showing the lot and serial number of counterfeit Ozempic

The FDA announced that it had seized counterfeit Ozempic injections on April 9. PSM testified at a congressional hearing.

April 7, 2025: A study examines FDA-OCI’s enforcement actions over a five-year period

April 7, 2025

A study examined the 130 enforcement actions undertaken by the U.S. Food and Drug Administration’s Office of Criminal Investigations from 2016 through 2021.

Colorado’s March 2025 Amended SIP Application

April 2, 2025

The state of Colorado submitted a revised application to the U.S. Food and Drug Administration to operation a Canadian drug importation plan in March. This blog post examines how the state’s application has changed over the years.

Colorado Department of Regulatory Agencies updates Joint Budget Committee on litigation costs

April 1, 2025

A March 12, 2025 memo said the state had paid more than $150,000 defending itself in a lawsuit Amgen had filed over plans to set an upper payment limit on its rheumatoid arthritis treatment, Enbrel.

Like your information on video? Subscribe to our YouTube playlist!

What have we learned about last year's fake Botox outbreak?

youtube-video-thumbnail
youtube-video-thumbnail

Why should fake drugs overseas matter to me? Watch.

Click the images below to see more recent videos.